Table 4 Baseline characteristics of patients in the first validation cohort. The patients all received biopsy-included pretreatment evaluations between 2007-2009

Subject number

45

Age

51.53 ± 10.30

<0.001

Gender

0.034

  Male

33 (73.33%)

  Female

12 (26.67%)

 ISHAK Fibrosis Stages

<0.001

  1

7 (15.56%)

  2

5 (11.11%)

  3

13 (28.89%)

  4

6 (13.33%)

  5

10 (22.22%)

  6

14 (31.11%)

 Piecemeal necrosis

0.07

  0

10 (22.22%)

  1

23 (51.11%)

  2

6 (13.33%)

  3

6 (13.33%)

 Confluent necrosis

0.165

  0

40 (88.89%)

  4

5 (11.11%)

 Focal (spotty) lytic necrosis, apoptosis and focal inflammation

0.329

  1

14 (31.11%)

  2

27 (60.00%)

  3

4 (8.89%)

 Portal inflammation

0.114

  0

2 (4.44%)

  1

13 (28.89%)

  2

6 (13.33%)

  3

23 (51.11%)

  4

1 (2.22%)

  HBV DNA (log10 IU/ml)

5.31 ± 1.68

<0.001

  HBsAg (log10 IU/ml)

2.79 ± 0.90

<0.001

  ALT (IU/L)

141.00 ± 124.94

0.087

  AST (IU/L)

91.29 ± 83.45

0.277

  Bilirubin (mg/dL)

0.90 ± 0.28

0.119

  Albumin (g/dL)

4.45 ± 0.28

0.196

  Gamma-glutamyltransferase (IU/L)

66.20 ± 65.26

0.626

  Platelet (1000/mm3)

179.36 ± 53.17

0.22

  Hemoglobin (g/dL)

14.69 ± 1.29

0.032